U.S. Semiconductors Stock News

Gaotu Techedu (NYSE:GOTU) just released its Q3 2025 results, recording revenue of ¥1.6 billion and a basic EPS of -¥0.61. For context, the company’s revenue has climbed from ¥1.0 billion in Q2 2024 to ¥1.6 billion this quarter. Basic EPS has improved from -¥1.65 in Q2 2024. Investors will be watching how the company works to narrow its losses and maintain the current pace of revenue growth as margins remain in focus this quarter. See our full analysis for Gaotu Techedu. Now that the headline...

J. M. Smucker (SJM) just reported results for Q2 2026, notching revenue of $2.3 billion and basic EPS of $2.26, with net income for the period coming in at $241.3 million. Over the past few quarters, revenue has hovered near the $2.1 to $2.3 billion mark while EPS has fluctuated, with recent periods swinging from negative to positive territory. Investors will be weighing these headline numbers in the context of volatile earnings margins as the company aims for sustained profitability. See our...

Petco Health and Wellness Company (WOOF) just reported Q3 2026 financials, posting revenue of $1.5 billion and basic EPS of $0.03. Over the past year, the company has seen revenue move from $6.2 billion to $6.0 billion with EPS tracking from -$4.95 to -$0.01, highlighting recent volatility in earnings. Margins remain under pressure, keeping the conversation tightly focused on the company’s path toward profitability. See our full analysis for Petco Health and Wellness Company. Next, we will...

American Woodmark (AMWD) just posted its Q2 2026 results, reporting revenue of $394.6 million and basic EPS of $0.42. Looking back, the company has seen revenue slide from $452.5 million in Q2 2025 to $394.6 million this quarter. EPS dropped from $1.81 to $0.42 over the same period. Margins compressed in the latest quarter, putting profitability in the spotlight for investors. See our full analysis for American Woodmark. Next up, we will compare these results with prevailing narratives to see...

Atour Lifestyle Holdings (NasdaqGS:ATAT) just released its Q3 2025 results, reporting revenue of ¥2.6 billion and basic EPS of ¥3.41. Over the past year, the company has seen revenue climb from ¥6.1 billion to ¥9.1 billion, up 20.4%, while EPS increased from ¥7.57 to ¥10.62, a 26.2% gain. Although net profit margins narrowed slightly compared to last year, the topline and EPS growth indicate the business is still delivering for shareholders. See our full analysis for Atour Lifestyle...

Thinking about whether CBRE Group offers real value right now? You are not alone, as more investors are questioning if the impressive run can last or if the stock has become too expensive. CBRE Group has shown strong performance lately, climbing 6.9% in just the past week, up 24.9% year-to-date, and delivering a massive 162.3% over the last 5 years. Market enthusiasm for CBRE Group has been fueled by a string of headline deals and sector momentum, including increased activity in commercial...

Analog Devices (ADI) just posted its FY 2025 fourth-quarter results, reporting revenue of $3.1 billion and basic EPS of $1.60. Over the past year, the company has seen revenue rise from $9.4 billion to $11.0 billion and basic EPS climb from $3.30 to $4.59. With margins now at 20.6%, investors will be watching how the company leverages improved profitability going forward. See our full analysis for Analog Devices. Let's see how the fresh results line up with the prevailing narratives in the...

Jiayin Group (NasdaqGM:JFIN) posted total revenue of ¥1.47 billion and basic EPS of ¥7.34 for the third quarter of 2025, accompanied by a net income of ¥376.49 million. The company has seen revenue move from ¥1.44 billion in Q3 2024 to ¥1.47 billion in Q3 2025, while EPS climbed from ¥5.07 to ¥7.34 over the same period. These results point to expanding margins and a favorable profit backdrop heading into the next reporting cycle. See our full analysis for Jiayin Group. Next up, we’re...

Zscaler (ZS) just released its Q1 2026 results, posting revenue of $788.1 million and a basic EPS of -$0.07. Looking at recent trends, the company has seen total revenue increase steadily from $592.9 million in Q4 2024 to $788.1 million in Q1 2026. EPS figures have remained negative during this period. Profitability has not yet been achieved, but the latest results may prompt investors to focus on the company’s potential for a margin turnaround in the upcoming quarters. See our full analysis...

Safe Bulkers (SB) has just released its Q3 2025 results, reporting total revenue of $73.1 million and basic EPS of $0.15, with net income of $15.8 million for the quarter. The company has seen revenue fluctuate over the past several quarters, decreasing from $78.5 million in Q2 2024 to a low of $64.3 million in Q1 2025 before rebounding this quarter. EPS also moved from $0.24 in Q2 2024 to a modest loss in Q2 2025, before returning to positive territory. Margins have compressed over the last...

Dell Technologies (DELL) just published its Q3 2026 results, posting revenue of $27.0 billion and basic EPS of $2.28. The company has seen revenue trend from $24.4 billion in Q3 last year to over $29.8 billion in Q2 and now $27.0 billion this quarter. EPS has moved from $1.61 a year ago to $2.36 in Q4 and $2.28 now. Solid profit margins and steady earnings trends continue to shape an intriguing picture for investors eyeing Dell's financial momentum. See our full analysis for Dell...

Lucky Strike Entertainment (LUCK) shares moved 3% higher today, catching some attention from investors. While there wasn’t a high-profile catalyst, moves like this often have traders checking for clues about shifting sentiment or potential upcoming announcements. See our latest analysis for Lucky Strike Entertainment. While Lucky Strike Entertainment’s latest 3% jump puts some spark back in the share price, longer-term momentum has been mixed. The 7-day share price return of 8.3% suggests...

In November 2025, Avidity Biosciences announced the launch of its Managed Access Program for the investigational therapy delpacibart zotadirsen for eligible Duchenne muscular dystrophy (DMD44) patients in the United States, aligning with the FDA on a 2026 accelerated approval submission pathway. This move reflects significant clinical and regulatory progress, as the therapy has earned multiple expedited designations from both U.S. and European regulators. We'll explore how securing FDA...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

As the U.S. stock market experiences a notable upswing with major indexes like the Nasdaq, S&P 500, and Dow Jones Industrial Average showing significant gains entering the Thanksgiving holiday, investors are increasingly attentive to opportunities that may be trading below their estimated value. In such a buoyant environment, identifying stocks that are potentially undervalued can provide investors with strategic entry points to capitalize on broader market optimism while maintaining a focus...

As the U.S. stock market continues its upward trajectory, with major indexes marking their biggest weekly rise since June, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, a term that may seem outdated yet remains significant, represent smaller or newer companies that can potentially offer substantial returns when they are built on solid financial foundations. In this article, we will explore three penny stocks that exhibit strong...

As major U.S. stock indices, including the Dow Jones, Nasdaq, and S&P 500, continue to experience gains entering the Thanksgiving holiday week, investors are keenly observing market dynamics that could impact small-cap stocks. With economic indicators showing mixed signals and broader market sentiment fluctuating, identifying promising yet lesser-known stocks becomes crucial for those looking to capitalize on potential opportunities in a dynamic environment.

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics recently announced the initiation of a rolling New Drug Application submission to the U.S. FDA for accelerated approval of zipalertinib, targeting EGFR exon 20 insertion-mutated non-small cell lung cancer after chemotherapy. This milestone builds on zipalertinib’s Breakthrough Therapy Designation and leverages data from the REZILIENT1 Phase 1/2 trial involving previously treated patients. We'll explore how progress toward FDA...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Hanesbrands (HBI) recently posted modest gains, with shares ticking up about 1% over the past week. Investors are weighing the company's mixed fundamentals as the consumer durables sector undergoes shifts and retail demand trends continue to evolve. See our latest analysis for Hanesbrands. Hanesbrands has seen its share price rebound slightly over the past quarter, but momentum remains mixed after a tough year, with a 1-year total shareholder return of -25.11%. While short bursts of optimism...

It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

To the annoyance of some shareholders, Here Group Limited ( NASDAQ:HERE ) shares are down a considerable 29% in the...

The board of Halliburton Company ( NYSE:HAL ) has announced that it will pay a dividend on the 24th of December, with...

Hillman Solutions Corp. ( NASDAQ:HLMN ), might not be a large cap stock, but it saw significant share price movement...